ClinicalTrials.gov
public full text
Public Domain
Intradermal Rabies Immunization Using NanoJect: A Comparative Study
The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies vaccine "Vaccin rabique Pasteur®" delivered with the NanoJect™ device by ID route.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)#448309
- Kinetics of rabies-neutralising antibodies in non-human primates after the injection of adjuvanted and inactivated rabies vaccine#280576
- Advances in nanotechnology for the diagnosis and management of autoimmune diseases.#143240
- Rabies Treatment by Exposure of Patient to X-Ray#888970
- Progress in Protein Nanoparticle Vaccines for Human Viral Diseases.#455235
Record · ID 862907
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive